checkAd

     926  0 Kommentare Lancet Publishes First Trial To Show Overall Survival Benefit Of Halaven® (eribulin) in People With Soft Tissue Sarcoma Sub-Types - Seite 4



    Media Enquiries
    Eisai
    Cressida Robson / Ben Speller
    +44(0)7908 314 155 / +44(0) 7951 078 795
    Cressida_Robson@eisai.net
    Ben_Speller@eisai.net

    Media Enquiries
    Tonic Life Communications
    Alex Davies / Emma Coughlan
    +44 (0)7720 496 472 / +44(0) 7772 534 646
    Alex.Davies@toniclc.com
    Emma.Coughlan@toniclc.com


    Lesen Sie auch


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4
    Verfasst von PR Newswire (engl.)
    Lancet Publishes First Trial To Show Overall Survival Benefit Of Halaven® (eribulin) in People With Soft Tissue Sarcoma Sub-Types - Seite 4 HATFIELD, England, February 11, 2016 /PRNewswire/ - An application to extend the indication of eribulin for the treatment of patients with unresectable locally advanced soft tissue sarcoma subtypes has been submitted in the EU  Full results of …